Next Article in Journal
Myeloid-Specific Deletion of the AMPKα2 Subunit Alters Monocyte Protein Expression and Atherogenesis
Previous Article in Journal
Novel Insights into the Effect of Hyperforin and Photodynamic Therapy with Hypericin on Chosen Angiogenic Factors in Colorectal Micro-Tumors Created on Chorioallantoic Membrane
Article

Amelioration of Behavioral Impairments and Neuropathology by Antiepileptic Drug Topiramate in a Transgenic Alzheimer’s Disease Model Mice, APP/PS1

Division of Immunopathology of the Nervous System, Institute of Pathology and Neuropathology, University of Tuebingen, Tuebingen D-72076, Germany
*
Author to whom correspondence should be addressed.
Int. J. Mol. Sci. 2019, 20(12), 3003; https://doi.org/10.3390/ijms20123003
Received: 25 April 2019 / Revised: 24 May 2019 / Accepted: 3 June 2019 / Published: 19 June 2019
(This article belongs to the Section Bioactives and Nutraceuticals)
Alzheimer’s disease (AD) is a neurodegenerative disease that is the main cause of dementia in the elderly. The aggregation of β-amyloid peptides is one of the characterizing pathological changes of AD. Topiramate is an antiepileptic drug, which in addition, is used in the treatment of many neuropsychiatric disorders. In this study, the therapeutic effects of topiramate were investigated in a transgenic mouse model of cerebral amyloidosis (APP/PS1 mice). Before, during, and after topiramate treatment, behavioral tests were performed. Following a treatment period of 21 days, topiramate significantly ameliorated deficits in nest-constructing capability as well as in social interaction. Thereafter, brain sections of mice were analyzed, and a significant attenuation of microglial activation as well as β-amyloid deposition was observed in sections from topiramate-treated APP/PS1 mice. Therefore, topiramate could be considered as a promising drug in the treatment of human AD. View Full-Text
Keywords: Alzheimer’s disease; APP/PS1 transgenic mouse; topiramate; amyloidosis Alzheimer’s disease; APP/PS1 transgenic mouse; topiramate; amyloidosis
Show Figures

Figure 1

MDPI and ACS Style

Owona, B.A.; Zug, C.; Schluesener, H.J.; Zhang, Z.-Y. Amelioration of Behavioral Impairments and Neuropathology by Antiepileptic Drug Topiramate in a Transgenic Alzheimer’s Disease Model Mice, APP/PS1. Int. J. Mol. Sci. 2019, 20, 3003. https://doi.org/10.3390/ijms20123003

AMA Style

Owona BA, Zug C, Schluesener HJ, Zhang Z-Y. Amelioration of Behavioral Impairments and Neuropathology by Antiepileptic Drug Topiramate in a Transgenic Alzheimer’s Disease Model Mice, APP/PS1. International Journal of Molecular Sciences. 2019; 20(12):3003. https://doi.org/10.3390/ijms20123003

Chicago/Turabian Style

Owona, Brice A., Caroline Zug, Hermann J. Schluesener, and Zhi-Yuan Zhang. 2019. "Amelioration of Behavioral Impairments and Neuropathology by Antiepileptic Drug Topiramate in a Transgenic Alzheimer’s Disease Model Mice, APP/PS1" International Journal of Molecular Sciences 20, no. 12: 3003. https://doi.org/10.3390/ijms20123003

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop